NCT07283198尚未招募2 期
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 160
- 主要终点
- Number and Severity of Treatment-emergent Adverse Events (TEAEs)
研究概览
简要总结
This is an open-label, multicenter, Phase II clinical study designed to evaluate the safety and efficacy of JSKN033 in the treatment of patients with advanced NSCLC. The study is divided into two phases: Part 1 (Dose Selection) and Part 2 (Cohort Expansion). Enrolled subjects are patients with locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) NSCLC who are not eligible for curative treatment. Part 1 (Dose Selection): It consists of two dose groups, with a maximum of 20 subjects enrolled in each group. Part 2 (Cohort Expansion): It consists of two cohorts, with a maximum of 60 subjects enrolled in each cohort.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects can understand the informed consent form,voluntarily participate in the study, and sign the informed consent form.
- •Subjects are≥18 years old on the day of signing the informed consent form, regardless of gender.
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or
- •Expected survival time ≥3 months.
- •Histologically or cytologically confirmed locally advanced or metastatic NSCLC (per AJCC 8th Edition Lung Cancer TNM Staging) that is not eligible for curative surgery and/or curative radiotherapy.
- •NSCLC confirmed to be no other known driver gene alterations for which first- line targeted therapy has been approved.
- •For Part 1(Dose Selection): Enrolled subjects are those with advanced unresectable or metastatic NSCLC who have failed or are intolerant to standard previous treatments, and have HER2 mutation or HER2 expression in tumor tissue.
- •For Part 2 (Cohort Expansion): Enrolled subjects are those with locally advanced or metastatic NSCLC who have not received prior systemic anti-tumor treatment for their advanced disease.
- •Per RECIST 1.1 criteria,subjects have at least one extracranial measurable lesion at baseline.
- •Subjects must provide tumor tissue samples.
- •Sufficient organ function.
- •Female subjects of childbearing potential or male subjects whose partners are of childbearing potential agree to use highly effective contraceptive measures from the time of signing the informed consent form until 24 weeks after the last dose.
排除标准
- •Presence of any small cell carcinoma component in the histological pathology.
- •History of other malignant tumors within 5 years prior to the first dose administration.
- •History of brainstem, meningeal, or spinal cord metastases/compression, or carcinomatous meningitis; presence of active brain metastases.
- •Imaging during the screening phase shows tumor invasion, compression, or location in surrounding vital organs.
- •Sufficient washout period from previous treatments prior to the first dose.
- •Presence of the following lung diseases or medical history leading to severe respiratory impairment.
- •Presence of risk factors related to interstitial lung disease (ILD) or non-infectious pneumonia.
- •Presence of cardiovascular and cerebrovascular diseases or risk factors.
- •Presence of uncontrolled infections.
- •Toxicity from previous anti-tumor treatment has not recovered to grade≤1 (per CTCAE v5.0).
- •Previous history of allogeneic bone marrow or organ transplantation.
- •Known allergy to any component of the study drug.
- •Pregnant and/or lactating women, or women planning to become pregnant during the study.
研究组 & 干预措施
Part 1 (Dose Selection) and Part 2 (Cohort Expansion)
Experimental
JSKN033 is administered at the predefined dose, once per treatment cycle.
干预措施: JSKN033 Injection (Drug)
结局指标
主要结局
Number and Severity of Treatment-emergent Adverse Events (TEAEs)
时间窗: Baseline up to 30 days after the last dose of study drug, up to 1 year
The incidence and severity of TEAEs and TRAEs (Treatment-related Adverse Events, graded according to NCI CTCAE 5.0), Serious AEs (SAEs), laboratory tests, etc.
Objective response rate (ORR)
时间窗: Up to 1 year after the last participant receives the last dose
ORR was defined as the proportion of subjects achieving Complete Response (CR) or Partial Response (PR)
次要结局
- PK parameter: trough concentration (Ctrough)(Post last dose up to Day 90)
- PK parameter: Clearance (CL)(Post last dose up to Day 90)
- PK parameter: Accumulation index (Rac)(Post last dose up to Day 90)
- PK parameter: Mean residence time (MRT)(Post last dose up to Day 90)
- Incidence of anti-drug antibodies (ADAs), antibody titers, and incidence of neutralizing antibodies(Post last dose up to Day 90)
- Overall survival (OS)(Up to 1 year after the last participant receives the last dose)
- PK parameter: Cmax(Post last dose up to Day 90)
- Duration of response (DoR)(Up to 1 year after the last participant receives the last dose)
- Disease control rate (DCR)(Up to 1 year after the last participant receives the last dose)
- Clinical benefit rate (CBR)(Up to 1 year after the last participant receives the last dose)
- PK parameter: Tmax(Post last dose up to Day 90)
- Progression-free Survival (PFS)(Up to 1 year after the last participant receives the last dose)
- PK parameter: AUC(Post last dose up to Day 90)
- PK parameter: Terminal Elimination Half-life (t1/2)(Post last dose up to Day 90)
- PK parameter: Volume of distribution (V)(Post last dose up to Day 90)
研究者
相似试验
尚未招募
1 期
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsNCT07279428Sichuan Baili Pharmaceutical Co., Ltd.33
招募中
2 期
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLCNCT07264816Sichuan Baili Pharmaceutical Co., Ltd.80
招募中
2 期
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)Ulcerative ColitisNCT07265570InSilico Medicine Hong Kong Limited80
尚未招募
1 期
Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid TumorsNCT07272590Qilu Pharmaceutical Co., Ltd.290
招募中
1 期
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsColorectal CancerNon-Small Cell Lung CancerNCT07261631Novartis Pharmaceuticals180